New immunotherapy cocktails aim to outsmart resistant ovarian cancer
NCT ID NCT04918186
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This Phase 2 study tests several immunotherapy drug combinations in women with platinum-resistant high-grade serous ovarian cancer, a type that no longer responds to standard chemotherapy. About 60 participants will receive one of five immunotherapy regimens to see which best shrinks tumors or slows progression. The goal is to find promising combinations for larger future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCCA - Kelowna
NOT_YET_RECRUITINGKelowna, British Columbia, V1Y 5L3, Canada
Contact Phone: •••-•••-••••
-
BCCA - Vancouver
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-••••
-
CHUM-Centre Hospitalier de l'Universite de Montreal
NOT_YET_RECRUITINGMontreal, Quebec, H2X 3E4, Canada
Contact Phone: •••-•••-••••
-
Odette Cancer Centre
NOT_YET_RECRUITINGToronto, Ontario, M4N 3M5, Canada
Contact Phone: •••-•••-••••
-
The Jewish General Hospital
NOT_YET_RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-••••
-
The University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••
-
University Health Network
NOT_YET_RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
What this could lead to
If successful, this could identify promising immunotherapy combinations to better control platinum-resistant ovarian cancer and guide larger future trials.
What could go wrong
This is an early Phase 2 platform study with only 60 participants. Not all drug combinations may prove effective, and side effects from immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.